Journal of Clinical Oncology, Vol 23, No 32 (November 10), 2005: pp. 8247-8252
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.03.1435
Management of Advanced Prostate Cancer After First-Line Chemotherapy
Dominik R. Berthold,
Cora N. Sternberg,
Ian F. Tannock
From the Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada; and the Division of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
Address reprint requests to Ian F. Tannock MD, PhD, FRCPC, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada; e-mail: Ian.Tannock{at}uhn.on.ca.
Hormone refractory prostate cancer (HRPC) causes substantial morbidity and mortality. There are increasing options for both first- and second-line therapy in the palliative treatment of patients with HRPC. Medications to control symptoms should first be optimized in patients with late-stage disease, and radiotherapy applied to dominant painful bone lesions. Docetaxel, mitoxantrone, satraplatin, and ixabepilone are active chemotherapeutic agents in the first- and/or second-line setting for patients with HRPC, and this may be true also of older drugs such as oral cyclophosphamide and vinorelbine. Radioisotopes such as strontium and samarium are useful for treatment of more generalized bone pain. Third-line hormonal maneuvers including glucocorticoids, ketoconazole, and estrogens can lead to further palliation in some patients, and there are provocative data that chemotherapy might restore hormonal sensitivity in a subset of patients.
D.R.B. is supported by a Prostate Cancer Research Training Grant to Princess Margaret Hospital from the Canadian Prostate Cancer Research Initiative.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. N. Sternberg, D. P. Petrylak, O. Sartor, J. A. Witjes, T. Demkow, J.-M. Ferrero, J.-C. Eymard, S. Falcon, F. Calabro, N. James, et al.
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
J. Clin. Oncol.,
November 10, 2009;
27(32):
5431 - 5438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, et al.
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Clin. Cancer Res.,
August 1, 2009;
15(15):
4954 - 4962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, and On behalf of the TAX 327 investigators
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Ann. Onc.,
October 1, 2008;
19(10):
1749 - 1753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. W. Yip, X. Mao, P.Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, and F.-F. Liu
Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5557 - 5569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Small and E. A. Klein
Challenges and Future Directions in the Prevention and Management of Prostate Cancer
J. Clin. Oncol.,
November 10, 2005;
23(32):
8143 - 8145.
[Full Text]
[PDF]
|
 |
|
|